Scientists and industry gather to discuss future advances in cell based assays

Advances in Cell Based Assays, 11th & 12th November, London UK

LONDON, LONDON, UNITED KINGDOM, September 17, 2014 /EINPresswire.com/ -- An array of pioneering scientists and market leaders will gather this autumn in Central London to discuss current and future advances in cell based assays.

Highlights at the 7th annual instalment which is set to take place on 11th and 12th November, will include an academic insight from the Centre for Stem Cells and Regenerative Medicine at King's College London.

Attendees will hear the Kings College Director of HipSci Cell Phenotyping, Davide Danovi, speak on the current challenges in the use of stem cells in phenotype screening. Other topics discussed in the talk entitled: High Content Analysis using Stem Cells for Disease Modelling and Drug Discovery include:

• Defining the boundaries between health and disease at a single cell level
• The human induced pluripotent

When asked about Advances in Cell Based Assays, Davide commented:

‘I had the privilege to participate to the Cell Based Assay conference organised by SMi in the past and enjoyed the mix in the backgrounds of participants from academia and industry and the scientific discussion. I look forward to participating again this year.'

“I hope I will be able to share some lessons learnt around the development of relevant assays based on stem cells and high content for disease modelling and drug discovery.”

Angiocrine Bioscience will be one of the key speakers this year providing an industry view as Director of Research, Dr Daniel Nolan, provides further insights into the VeraVec™ platform.

The talk will discuss recent works demonstrating how the chemoresistant niche within cancer involves the vasculature, a look into how the vascular stem cell niche is capable of expanding stem cells in vitro while maintaining potency and engraftability, plus VeraVec™ amenability to 3D and co-culture assays for screening purposes.

When asked about his paper Daniel said:

“While there are some familiar themes they will recognize from recent advances in cell-based therapies, Angiocrine Bioscience’s VeraVec platform has been called “one of the first practical therapies”. As many groups have been trying to achieve a reductionist and overly simplified approach to stem cell biology, I will endeavour to demonstrate the importance and complexity of the stem cell niche which is by no means reductionist.”

On the future of the industry he commented:

“The future of cell based assays will consist of numerous cell types simultaneously. This is already evident with organ-on-a-chip models which will continue to advance and become a tremendous force in drug discovery and enabling “failing early” to allow for the truly beneficial factors to rise to the top faster and cheaper.”

“Many people know a great deal about a very specific topic, however if the future is going to be in the multi-plexed systems, there is going to need to be a tremendous amount of education required.”

Further details including the full interviews, attendee snap shot and brochure are available to view online at www.cellbasedassay.co.uk

Advances in Cell Based Assays
11-12 November 2014
Marriott Regents Park Hotel, London UK
www.cellbasedassay.co.uk

--- END ---
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here